Endovascular Engineering, Inc. (E2) has secured an oversubscribed Series B financing round of $42 million to advance its innovative clot removal technology for venous thromboembolism (VTE). The funding round was co-led by 415 Capital and S3 Ventures, with additional participation from Panakēs Partners, M&L Healthcare, and continued support from founding investor Santé Ventures. Two global strategic investors and Cordis also made substantial commitments.
Strategic Focus on Pulmonary Embolism Treatment
The capital infusion comes at a crucial time as E2 approaches completion of enrollment in its ENGULF pivotal trial, which is evaluating the company's flagship Hēlo PE Thrombectomy System. Pulmonary embolism, the third leading cause of cardiovascular death, represents a significant unmet medical need in interventional medicine.
"This financing represents more than capital – it validates our technology platform and positions us to revolutionize PE treatment," said E2's CEO Dan Rose. "With strong support from sophisticated healthcare investors like 415 Capital and S3 Ventures, we are well-positioned to establish the Hēlo PE System as the gold standard in mechanical thrombectomy for pulmonary embolism."
Innovative Technology Platform
The Hēlo Thrombectomy System introduces a breakthrough in clot removal technology through its patented dual-action mechanism. The system uniquely combines powerful aspiration capabilities with advanced mechanical clot disruption, while maintaining a small-profile catheter design that enables efficient single-pass procedures.
Dr. Ruben Osnabrugge, Partner at 415 Capital, emphasized the technology's potential: "E2 is developing a best-in-class therapy for PE. Its differentiated technology and vision align closely with our mission to advance novel cardiovascular therapies, and we are proud to support E2 as it advances the Hēlo PE thrombectomy platform towards FDA approval."
Strategic Leadership Expansion
As part of the financing, E2 has strengthened its board of directors with the appointment of Dr. Ruben Osnabrugge from 415 Capital and Brian R. Smith from S3 Ventures. Smith expressed confidence in the platform's potential, stating, "We are truly impressed by E2's next-generation platform technology for VTE and see this as a solution to dramatically scale the mechanical thrombectomy market and improve the lives of patients."
Comprehensive System Development
The Hēlo PE Thrombectomy System is currently for investigational use only and has not yet received commercial approval. The technology is part of a comprehensive system designed to enhance both patient care and procedural efficiency, representing E2's commitment to transforming the standard of care in VTE treatment through the convergence of clinical insight and engineering excellence.
